← Eichor
Study identifier: NCT05504291 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Condition: Bilateral Retinoblastoma · Childhood Intraocular Retinoblastoma · Group D Retinoblastoma  ·  Sponsor: Children's Oncology Group

PhasePhase 2
Planned participants26
Who can joinAll sexes, N/A to 18 Years
Healthy volunteersNo

About this study

This phase II trial tests the safety and side effects of adding melphalan (by injecting it into the eye) to standard chemotherapy in early treatment of patients with retinoblastoma (RB). RB is a type of cancer that forms in the tissues of the retina (the light-sensitive layers of nerve tissue at the back of the eye). It may be hereditary or nonhereditary (sporadic). RB is considered harder to treat (higher risk) when there are vitreous seeds present. Vitreous seeds are RB tumors in the jelly-like fluid of the eye (called the vitreous humor). The term, risk, refers to the chance of the cancer not responding to treatment or coming back after treatment. Melphalan is in a class of medications called alkylating agents. It may kill cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Other chemotherapy drugs given during this trial include carboplatin, vincristine, and etoposide. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cel…

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (20)

Children's Hospital of AlabamaBirmingham, Alabama, United StatesRecruiting
Children's Hospital Los AngelesLos Angeles, California, United StatesRecruiting
Lucile Packard Children's Hospital Stanford UniversityPalo Alto, California, United StatesRecruiting
Children's Hospital ColoradoAurora, Colorado, United StatesRecruiting
Children's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta, Georgia, United StatesRecruiting
C S Mott Children's HospitalAnn Arbor, Michigan, United StatesRecruiting
Washington University School of MedicineSt Louis, Missouri, United StatesRecruiting
Duke University Medical CenterDurham, North Carolina, United StatesRecruiting
Children's Hospital Medical Center of AkronAkron, Ohio, United StatesRecruiting
Cleveland Clinic FoundationCleveland, Ohio, United StatesRecruiting
Saint Jude Children's Research HospitalMemphis, Tennessee, United StatesRecruiting
Dell Children's Medical Center of Central TexasAustin, Texas, United StatesRecruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05504291